MX2020002939A - Metodos de inactivacion de virus utilizando n-metilglutamida y sus derivados. - Google Patents
Metodos de inactivacion de virus utilizando n-metilglutamida y sus derivados.Info
- Publication number
- MX2020002939A MX2020002939A MX2020002939A MX2020002939A MX2020002939A MX 2020002939 A MX2020002939 A MX 2020002939A MX 2020002939 A MX2020002939 A MX 2020002939A MX 2020002939 A MX2020002939 A MX 2020002939A MX 2020002939 A MX2020002939 A MX 2020002939A
- Authority
- MX
- Mexico
- Prior art keywords
- solution
- biological product
- interest
- methylglucamide
- product solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
- A01N37/20—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof containing the group, wherein Cn means a carbon skeleton not containing a ring; Thio analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0088—Liquid substances
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13061—Methods of inactivation or attenuation
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pest Control & Pesticides (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Plant Pathology (AREA)
- Agronomy & Crop Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta divulgación se refiere a métodos para usar en la inactivación de virus. Los métodos de inactivación de virus con N-metilglucamidas son aplicables al proceso de purificación de medicamentos biológicamente activos como subunidades de proteínas, proteínas (enzimas, factores, etc.), proteínas recombinantes, anticuerpos, vacunas o productos terapéuticos genéticos. Los detergentes utilizados en este método se basan en múltiples homólogos de N-metilglucamida, que consisten en un resto de glucosa hidrofílica y una cola de ácido graso hidrofóbico, unidos por un enlace amida. Además, estos detergentes a base de azúcar son no iónicos por naturaleza, lo que no interrumpe la proteína del fármaco, los productos biológicos del plasma, la vacuna viral sin envoltura, o las partículas virales adenoasociadas. Un método para purificar una solución de un producto biológico de interés que tiene un contaminante de virus envuelto no identificado, que incluye incubar una solución de producto biológico de interés con una solución estándar, inactivando cualquier posible contaminante de virus envuelto presente en la solución de la etapa (a), midiendo el virus inactivado presente en la solución final de la etapa (b), incubando una solución de producto biológico separado de interés, con una solución de N-metilglucamida, midiendo el virus inactivado presente en la solución final de la etapa (d), y comparando los resultados de la solución final con las soluciones de la etapa (c) y la etapa (e).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762559812P | 2017-09-18 | 2017-09-18 | |
| PCT/US2018/050579 WO2019055463A1 (en) | 2017-09-18 | 2018-09-12 | METHODS OF INACTIVATING VIRUSES USING N-METHYLGLUCAMIDE AND ITS DERIVATIVES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002939A true MX2020002939A (es) | 2020-07-22 |
Family
ID=63762999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002939A MX2020002939A (es) | 2017-09-18 | 2018-09-12 | Metodos de inactivacion de virus utilizando n-metilglutamida y sus derivados. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11564392B2 (es) |
| EP (1) | EP3684921A1 (es) |
| JP (2) | JP7317005B2 (es) |
| KR (1) | KR20200052370A (es) |
| CN (1) | CN111108193A (es) |
| AU (1) | AU2018331357A1 (es) |
| BR (1) | BR112020005229A2 (es) |
| CA (1) | CA3075853A1 (es) |
| IL (1) | IL273229A (es) |
| MX (1) | MX2020002939A (es) |
| PE (1) | PE20201167A1 (es) |
| SG (1) | SG11202002449PA (es) |
| TW (1) | TWI834623B (es) |
| WO (1) | WO2019055463A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11564392B2 (en) * | 2017-09-18 | 2023-01-31 | Bayer Healthcare Llc | Methods of inactivation of viruses using n-methlyglucamide and its derivatives |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
| DE3704550A1 (de) * | 1987-02-13 | 1988-08-25 | Behringwerke Ag | Verfahren zur inaktivierung huellhaltiger viren in mittels einer zelle in vitro hergestellten protein-praeparationen |
| DE4103800A1 (de) | 1990-09-27 | 1992-04-02 | Helmuth Schmoock | Folie |
| DE4125625C2 (de) * | 1991-08-02 | 1999-12-02 | Octapharma Ag Glarus | Verfahren zur Herstellung von virusinaktivierten Immunglobulinlösungen |
| AU6653094A (en) * | 1992-12-16 | 1994-07-04 | Immuno Aktiengesellschaft | Process for preparing a virus-safe biological composition |
| US5695928A (en) | 1993-12-10 | 1997-12-09 | Novartis Corporation | Rapid immunoassay for detection of antibodies or antigens incorporating simultaneous sample extraction and immunogenic reaction |
| DE19528221C2 (de) | 1995-08-01 | 1998-10-22 | Blutspendedienst Der Drk Lande | Verfahren zur Herstellung eines virussicheren, therapeutischen Präparates aus Humanplasma |
| CA2175719A1 (en) | 1996-05-03 | 1997-11-04 | Brian J. Underdown | Compositions and methods for protection against immunologically diverse isolates of influenza virus |
| US6093743A (en) | 1998-06-23 | 2000-07-25 | Medinox Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| CA2309633C (en) | 1998-10-23 | 2010-12-14 | Idea Innovative Dermale Applikationen Gmbh | Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates |
| US20020127587A1 (en) | 2001-02-13 | 2002-09-12 | Domenica Simms | Methods and compositions for isolation of biological macromolecules |
| EP1691198B1 (en) | 2003-10-28 | 2010-10-20 | Advanced Life Science Institute, Inc. | Method of detecting hepatitis c virus |
| JP4131850B2 (ja) | 2003-12-04 | 2008-08-13 | アークレイ株式会社 | インフルエンザウイルスの免疫学的測定方法 |
| KR20070012838A (ko) | 2004-05-19 | 2007-01-29 | 가부시끼가이샤 센단세메이가가꾸겐큐죠 | Ｂ형간염 바이러스의 검출방법 |
| EP1806363B1 (en) | 2004-09-22 | 2013-09-04 | Advanced Life Science Institute, Inc. | METHOD OF DETECTING HEPATITIS B VIRUS s ANTIGEN |
| SG177887A1 (en) * | 2006-12-15 | 2012-02-28 | Schering Plough Ltd | Method for replicating influenza virus in culture |
| CN101610787B (zh) * | 2006-12-15 | 2013-07-03 | 先灵-普劳有限公司 | 在培养物中复制流感病毒的方法 |
| CN101081298A (zh) | 2007-06-26 | 2007-12-05 | 陈少莺 | 一种猪伪狂犬病新型亚单位疫苗制备方法 |
| WO2009129470A2 (en) * | 2008-04-18 | 2009-10-22 | Nanobio Corporation | Methods for treating herpes virus infections |
| US9144606B2 (en) | 2008-04-21 | 2015-09-29 | Nanobio Corporation | Nanoemulsion influenza vaccine |
| WO2010014903A1 (en) | 2008-07-31 | 2010-02-04 | Massachusetts Institute Of Technology | Multiplexed olfactory receptor-based microsurface plasmon polariton detector |
| JP2010077091A (ja) | 2008-09-26 | 2010-04-08 | Beacle Inc | Ｂ型肝炎ウイルスタンパク質中空バイオナノ粒子とリポソームを用いたｓｉＲＮＡの内包と細胞選択的なｓｉＲＮＡの導入方法 |
| EP2729169A1 (en) | 2011-07-06 | 2014-05-14 | Nanobio Corporation | Human respiratory syncytial virus vaccine |
| DK2879691T3 (da) * | 2012-08-06 | 2019-06-11 | Biogen Ma Inc | Fremgangsmåder og sammensætninger til inaktivering af kappebærende vira |
| WO2015036549A1 (en) | 2013-09-13 | 2015-03-19 | Löving Robin | Antigen and method for production thereof |
| KR102238133B1 (ko) * | 2013-11-15 | 2021-04-09 | 제넨테크, 인크. | 환경-친화적 세제를 사용한 바이러스 불활성화 방법 |
| JP2016182112A (ja) | 2015-03-25 | 2016-10-20 | 東ソー株式会社 | ウイルスからの核酸抽出試薬 |
| US11564392B2 (en) * | 2017-09-18 | 2023-01-31 | Bayer Healthcare Llc | Methods of inactivation of viruses using n-methlyglucamide and its derivatives |
-
2018
- 2018-09-12 US US16/646,600 patent/US11564392B2/en active Active
- 2018-09-12 WO PCT/US2018/050579 patent/WO2019055463A1/en unknown
- 2018-09-12 PE PE2020000381A patent/PE20201167A1/es unknown
- 2018-09-12 EP EP18782592.2A patent/EP3684921A1/en active Pending
- 2018-09-12 TW TW107132077A patent/TWI834623B/zh active
- 2018-09-12 BR BR112020005229-9A patent/BR112020005229A2/pt unknown
- 2018-09-12 MX MX2020002939A patent/MX2020002939A/es unknown
- 2018-09-12 KR KR1020207010807A patent/KR20200052370A/ko not_active Application Discontinuation
- 2018-09-12 AU AU2018331357A patent/AU2018331357A1/en active Pending
- 2018-09-12 CN CN201880060493.4A patent/CN111108193A/zh active Pending
- 2018-09-12 CA CA3075853A patent/CA3075853A1/en active Pending
- 2018-09-12 SG SG11202002449PA patent/SG11202002449PA/en unknown
- 2018-09-12 JP JP2020515732A patent/JP7317005B2/ja active Active
-
2020
- 2020-03-11 IL IL273229A patent/IL273229A/en unknown
-
2022
- 2022-10-28 US US17/975,645 patent/US20230143494A1/en not_active Abandoned
-
2023
- 2023-07-18 JP JP2023116731A patent/JP2023139096A/ja active Pending
- 2023-12-13 US US18/538,562 patent/US20240196891A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230143494A1 (en) | 2023-05-11 |
| US20200260727A1 (en) | 2020-08-20 |
| RU2020113752A (ru) | 2021-10-20 |
| TW201925163A (zh) | 2019-07-01 |
| IL273229A (en) | 2020-04-30 |
| WO2019055463A1 (en) | 2019-03-21 |
| TWI834623B (zh) | 2024-03-11 |
| AU2018331357A1 (en) | 2020-04-02 |
| SG11202002449PA (en) | 2020-04-29 |
| BR112020005229A2 (pt) | 2020-09-24 |
| CN111108193A (zh) | 2020-05-05 |
| EP3684921A1 (en) | 2020-07-29 |
| KR20200052370A (ko) | 2020-05-14 |
| RU2020113752A3 (es) | 2022-04-22 |
| US11564392B2 (en) | 2023-01-31 |
| US20240196891A1 (en) | 2024-06-20 |
| JP7317005B2 (ja) | 2023-07-28 |
| JP2023139096A (ja) | 2023-10-03 |
| CA3075853A1 (en) | 2019-03-21 |
| JP2020533987A (ja) | 2020-11-26 |
| PE20201167A1 (es) | 2020-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ramon et al. | The specialized proresolving mediator 17-HDHA enhances the antibody-mediated immune response against influenza virus: a new class of adjuvant? | |
| Weigel et al. | A flow-through chromatography process for influenza A and B virus purification | |
| Hütter et al. | Toward animal cell culture–based influenza vaccine design: viral hemagglutinin N-glycosylation markedly impacts immunogenicity | |
| Prasad et al. | Presentation of cryptic peptides by MHC class I is enhanced by inflammatory stimuli | |
| ES2653197T3 (es) | Procedimiento para producir antígeno ortomixoviral y vacunas | |
| CN110132801B (zh) | 高通量量化及分析口蹄病病毒及相关产物的方法 | |
| JP6373376B2 (ja) | 残留細胞培養不純物の除去 | |
| Stegelmeier et al. | Type I interferon-mediated regulation of antiviral capabilities of neutrophils | |
| FR2723740A1 (fr) | Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications | |
| Feng et al. | Coxsackievirus cloverleaf RNA containing a 5′ triphosphate triggers an antiviral response via RIG-I activation | |
| Hein et al. | OP7, a novel influenza A virus defective interfering particle: production, purification, and animal experiments demonstrating antiviral potential | |
| Bawage et al. | Synthetic mRNA expressed Cas13a mitigates RNA virus infections | |
| JP2012507272A (ja) | 新規な方法 | |
| McKellar et al. | Mammalian and avian host cell influenza A restriction factors | |
| MX2020002939A (es) | Metodos de inactivacion de virus utilizando n-metilglutamida y sus derivados. | |
| Patel et al. | Molecular and immunogenic characterization of BHK-21 cell line adapted CVS-11 strain of rabies virus and future prospect in vaccination strategy | |
| Kang et al. | ISG20 inhibits bluetongue virus replication | |
| Zou et al. | Use of praziquantel as an adjuvant enhances protection and Tc-17 responses to killed H5N1 virus vaccine in mice | |
| Krishna et al. | Differential induction of type I and type III interferons by swine and human origin H1N1 influenza a viruses in porcine airway epithelial cells | |
| Liu et al. | p53 suppresses the inflammatory response following respiratory syncytial virus infection by inhibiting TLR2 | |
| Mi et al. | Avian influenza virus H5N1 induces rapid interferon-beta production but shows more potent inhibition to retinoic acid-inducible gene I expression than H1N1 in vitro | |
| Li et al. | Cellular protein GLTSCR2: a valuable target for the development of broad-spectrum antivirals | |
| JP2023524015A (ja) | 使い捨て培養工程システムを用いたインフルエンザウイルス生産方法及びインフルエンザウイルス抗原精製条件の迅速確認試験 | |
| Morozova et al. | Antiviral properties and toxicity of Ag-cystine complex | |
| Kovner et al. | Morphofunctional status and the role of mononuclear phagocyte system lung compartment in the pathogenesis of influenza A (H5N1) in mammals |